Observational study on the safety and effectiveness of SARS-CoV-2 vaccination in patients with lung cancer

E. Nadal , T. Morán , A. Estival , M.Á. Sala , M. Antoñanzas , J.G. González , M.P. Diz-Taín , M. Martínez , E. Azcona , J. Baena , B. Campos , J.D. Cumplido , S. Cerezo , A. Díaz-Serrano , M. Guirado , X. Mielgo , M. Saigí , Z. Vidales , Spanish Lung Cancer Group
{"title":"Observational study on the safety and effectiveness of SARS-CoV-2 vaccination in patients with lung cancer","authors":"E. Nadal ,&nbsp;T. Morán ,&nbsp;A. Estival ,&nbsp;M.Á. Sala ,&nbsp;M. Antoñanzas ,&nbsp;J.G. González ,&nbsp;M.P. Diz-Taín ,&nbsp;M. Martínez ,&nbsp;E. Azcona ,&nbsp;J. Baena ,&nbsp;B. Campos ,&nbsp;J.D. Cumplido ,&nbsp;S. Cerezo ,&nbsp;A. Díaz-Serrano ,&nbsp;M. Guirado ,&nbsp;X. Mielgo ,&nbsp;M. Saigí ,&nbsp;Z. Vidales ,&nbsp;Spanish Lung Cancer Group","doi":"10.1016/j.esmorw.2025.100125","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>We aimed to determine the safety and effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in terms of protection from infection and reduced coronavirus disease 2019 (COVID-19) severity in lung cancer patients. We also analysed the toxicities related to antineoplastic treatments and the influence of infection before or after vaccination on overall survival (OS).</div></div><div><h3>Patients and methods</h3><div>This cohort, multicentric, retrospective study was carried out between April 2021 and January 2022 in 27 Spanish hospitals. We included all patients ≥18 years old with lung cancer of any histology and stage who received a European Medicines Agency-approved (up to January 2022) SARS-CoV-2 vaccine. We collected patient follow-up data up to 3 months after vaccination.</div></div><div><h3>Results</h3><div>Seven hundred and ninety-four patients were included in the analysis. Most patients were male (511, 64.4%) and the mean age was 66.0 years (standard deviation: 9.9 years). Five hundred and ninety-three (74.7%) patients received three vaccine doses. Two hundred and thirty-five (29.6%) patients reported vaccine-related adverse events. No grade 5 and only one grade 4 vaccine-related adverse event was observed. Two hundred and sixty-two (33.0%) patients had at least one adverse event related to cancer treatment; no grade 5 adverse events were reported and 21 grade 4 were observed. Fifty-eight (7.3%) patients were infected with SARS-CoV-2 after being vaccinated; 10 (17.2%) required hospitalisation and none of them needed intensive care nor died. No significant difference was observed between the OS of patients infected by SARS-CoV-2 before receiving the first vaccine dose and those not infected (<em>P</em> = 0.441).</div></div><div><h3>Conclusions</h3><div>Our real-world data supported the safety and effectiveness of SARS-CoV-2 vaccines in patients with lung cancer. SARS-CoV-2 vaccines protected most of our population from infection, and those infected developed mild-to-moderate disease.</div></div>","PeriodicalId":100491,"journal":{"name":"ESMO Real World Data and Digital Oncology","volume":"8 ","pages":"Article 100125"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESMO Real World Data and Digital Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949820125000141","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background

We aimed to determine the safety and effectiveness of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in terms of protection from infection and reduced coronavirus disease 2019 (COVID-19) severity in lung cancer patients. We also analysed the toxicities related to antineoplastic treatments and the influence of infection before or after vaccination on overall survival (OS).

Patients and methods

This cohort, multicentric, retrospective study was carried out between April 2021 and January 2022 in 27 Spanish hospitals. We included all patients ≥18 years old with lung cancer of any histology and stage who received a European Medicines Agency-approved (up to January 2022) SARS-CoV-2 vaccine. We collected patient follow-up data up to 3 months after vaccination.

Results

Seven hundred and ninety-four patients were included in the analysis. Most patients were male (511, 64.4%) and the mean age was 66.0 years (standard deviation: 9.9 years). Five hundred and ninety-three (74.7%) patients received three vaccine doses. Two hundred and thirty-five (29.6%) patients reported vaccine-related adverse events. No grade 5 and only one grade 4 vaccine-related adverse event was observed. Two hundred and sixty-two (33.0%) patients had at least one adverse event related to cancer treatment; no grade 5 adverse events were reported and 21 grade 4 were observed. Fifty-eight (7.3%) patients were infected with SARS-CoV-2 after being vaccinated; 10 (17.2%) required hospitalisation and none of them needed intensive care nor died. No significant difference was observed between the OS of patients infected by SARS-CoV-2 before receiving the first vaccine dose and those not infected (P = 0.441).

Conclusions

Our real-world data supported the safety and effectiveness of SARS-CoV-2 vaccines in patients with lung cancer. SARS-CoV-2 vaccines protected most of our population from infection, and those infected developed mild-to-moderate disease.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Observational study on the safety and effectiveness of SARS-CoV-2 vaccination in patients with lung cancer Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study Core variables for real-world clinicogenomic data collection in precision oncology Cancer in public figures, 2010-2020 Definitions, measurement, and reporting of progression-free survival in randomized clinical trials and observational studies of patients with advanced non-small-cell lung cancer treated with immunotherapy: a scoping review
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1